Histone deacetylase 6 (HDAC6)

Overview

Histone deacetylase 6 (HDAC6) is a cytoplasmic histone deacetylase and a member of the class IIb HDAC family. Unlike many other HDACs that primarily regulate chromatin in the nucleus, HDAC6 is best known for deacetylating non-histone substrates in the cytoplasm, thereby influencing processes such as protein quality control, intracellular transport, stress responses, and cell signaling. Because of these functions, HDAC6 has attracted substantial interest as a therapeutic target in cancer, neurodegenerative disease, inflammatory disorders, and metabolic disease.

Biologically, HDAC6 is often discussed as a regulator of proteostasis and cellular stress pathways. In recent research, it has been linked to stress granule biology through deacetylation of G3BP1, to neuronal and pain-related signaling in brain regions such as the central amygdala and parabrachial nuclei, and to disease-relevant pathways involving β-tubulin (TUBB), BCL2 apoptosis regulator, and Cyclooxygenase 2 (COX-2). Its selective inhibition is being explored as a strategy to modulate disease phenotypes while potentially avoiding some of the broader effects associated with class I HDAC inhibition.

Recent Publications Summary

Recent studies have continued to position Histone deacetylase 6 (HDAC6) as a versatile therapeutic target across cancer, neurodegeneration, pain, and inflammatory disease. In endocrine-resistant breast cancer, a dual ERα/HDAC6 PROTAC, V-12c, selectively degraded both targets in vitro and in vivo, suppressed tumor growth in tamoxifen-resistant models, and outperformed single-target approaches by inducing cell-cycle arrest, apoptosis, autophagy-lysosome disruption, and ferroptosis 42411996Jul. In melanoma, the selective HDAC6 inhibitor WT-161 was identified as a radiosensitizer; HDAC6 inhibition disrupted interactions with DNA damage repair proteins DDB2 and DEK, suppressed DNA repair pathway gene expression, increased irradiation-induced DNA damage, and promoted tumor regression, supporting HDAC6 as a biomarker of radiation response 41713838Feb.

Several publications focused on the discovery and optimization of selective HDAC6 inhibitors with disease-relevant biological activity. Taginostat, a quinolone-based HDAC6 inhibitor, promoted apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo by restoring p66Shc expression and activating STAT4, with comparable effects seen after HDAC6 silencing 42400850Jul. New thiazole-linked N-hydroxypropanamide derivatives yielded a potent HDAC6 inhibitor, 5h, with strong selectivity over HDAC1; this compound increased neurogenesis-related gene expression in neural progenitor cells and improved memory performance in a mouse model of scopolamine-induced impairment 42241502Jun. Additional medicinal chemistry efforts produced diphenyl-1,2,4-oxadiazole HDAC6 inhibitors that alleviated inflammatory and paclitaxel-induced neuropathic pain in rodent models, and indole-based hydroxamate derivatives that preferentially inhibited HDAC6 in the low nanomolar range while showing antiproliferative activity in cancer cell systems 41894848Mar41880788Mar.

HDAC6 has also been explored in multitarget strategies for complex diseases. A dual cGAS/HDAC inhibitor, 31h, showed potent cGAS inhibition with moderate HDAC6 activity and demonstrated efficacy in murine models of inflammatory bowel disease and Aicardi-Goutières syndrome, illustrating the rationale for combined modulation of cGAS-related inflammatory signaling and HDAC activity 42268702Jun. In Alzheimer’s disease research, 1,5-diarylpyrazole-based dual COX-2/HDAC6 inhibitors were developed, with lead compound 11e showing potent activity against both targets and neuroprotective effects including increased α-tubulin acetylation, reduced proinflammatory mediators such as TNF-α, enhanced amyloid-β clearance, and reduced Tau hyperphosphorylation 41785827Mar.

Other studies linked HDAC6 to pain and neuropsychiatric phenotypes. In IBS-like rats, HDAC6 expression in the central amygdala was associated with visceral hypersensitivity and affective comorbidities, and intra-CeA administration of the selective HDAC6 inhibitor ACY-738 alleviated pain- and anxiety-like behaviors 41797088Mar. In preclinical neurodegeneration work, the next-generation HDAC6 inhibitor EKZ-438 was reported to have high selectivity, low-nanomolar potency, and CNS penetrance, with development aimed at amyotrophic lateral sclerosis and frontotemporal dementia 41061670Oct. Collectively, these publications reinforce HDAC6 as a druggable node in oncology, neurology, pain, and inflammation, with both selective inhibitors and dual-target agents showing promising mechanistic and therapeutic profiles 42411996Jul42400850Jul42241502Jun41894848Mar41797088Mar41785827Mar41713838Feb41061670Oct.

What Changes, What Holds

1. HDAC6 now looks like a context-dependent therapeutic node rather than only a cytoplasmic deacetylase target
NEW DIRECTION Endocrine-resistant breast cancer and melanoma extend HDAC6 from the baseline’s general roles in proteostasis, stress signaling, and disease targeting into more specific treatment logic: it can be co-targeted with ERα or used to sensitize tumors to radiation. That broadens its therapeutic relevance, but the evidence is still preclinical and mechanism-heavy, so the practical question is which tumor contexts truly depend on HDAC6 and whether these combinations will translate beyond model systems 42411996Jul41713838Feb.

2. Selective HDAC6 inhibition is emerging as a disease-modifying strategy across cancer, cognition, and pain
REINFORCES These studies strengthen the baseline view that HDAC6 is a druggable cytoplasmic regulator with broad therapeutic potential, while adding more examples of selective inhibitors producing phenotype-relevant effects. The main change is not a new biological role but a sharper sense that HDAC6-directed chemistry can be tuned toward distinct outcomes, from leukemic apoptosis to neurogenesis and analgesia. What remains unsettled is whether these benefits reflect on-target biology robustly enough to support clinical development 42400850Jul42241502Jun.

3. Dual-target HDAC6 strategies may be more useful than HDAC6 inhibition alone in complex inflammatory and neurodegenerative disease
NEW DIRECTION The new work goes beyond the baseline’s emphasis on selective inhibition by showing that HDAC6 can serve as one half of a multitarget design, paired with cGAS or COX-2. That does not overturn HDAC6’s established roles, but it does shift how it may be used: not just as a standalone target, but as part of combination pharmacology aimed at inflammatory signaling and neuroprotection. Whether the added complexity improves efficacy enough to justify it still needs stronger validation 42268702Jun41785827Mar.

4. HDAC6 inhibition is now linked to affective symptoms and CNS-penetrant neurodegeneration programs, not only pain signaling
NEW DIRECTION The central amygdala findings extend the baseline’s pain-related and brain-region-specific biology into visceral hypersensitivity with anxiety-like behavior, broadening HDAC6’s relevance to neuropsychiatric comorbidity. The CNS-penetrant inhibitor adds a translational angle for neurodegenerative disease, but it does not yet establish clinical utility. Together these results suggest HDAC6 may matter in circuit-level symptom control as well as disease modification, though the evidence remains preclinical and indication-specific 41797088Mar41061670Oct.

Overview update candidates: HDAC6 as a radiosensitization biomarker in melanoma; dual-target HDAC6 strategies with cGAS or COX-2; HDAC6 involvement in affective comorbidity alongside visceral pain.